Inspection Record

Novel Biome Solutions Inc. — Health Canada Inspection Findings

Health CanadaInspected 2023-02-08 16 findingsLaboratory and QC controlsOther quality systemComputer system validationEquipment and facilityContamination controlValidation and qualificationMaterial and supplier control

View the regulator's official source The source document is always the basis for judgement.

Findings

1Laboratory and QC controls

Qualified personnel did not adequately supervise the fabrication, packaging, labelling, testing, and/or storage of drugs. The job descriptions for personnel, the authority given to personnel, and/or the delegation of duties was inadequate and/or undocumented. The education, experience, and/or oversight of the individual in charge of the quality control department was inadequate. The duties of the individual in charge of the manufacturing department were delegated to an unqualified individual. The training of personnel in good manufacturing practices and/or the maintenance of records was inadequate.

2Other quality system

The recorded information or details were inadequate.

3Laboratory and QC controls

There was no evidence of a functioning and/or independent quality control department.

4Laboratory and QC controls

The specifications were not in writing and/or approved by the person in charge of the quality control department or the designated alternative. Lots or batches of finished product were not examined or tested against the specifications before they were fabricated or sold.

5Computer system validation

The calibration, inspection, and/or qualification of the equipment, including computerized systems, was inadequate. The usage logs for the equipment used for significant processing and/or testing operations were inadequate.

6Equipment and facility

The design of the drug stability study was inadequate and/or not justified with a documented rationale. "The maintenance of records was inadequate.

7Other quality system

The written procedures and records for retaining samples were inadequate.

8Laboratory and QC controls

The quality control department's selection of a laboratory for testing and/or examination was inadequate.

9Laboratory and QC controls

The quality control department did not approve the specifications for packaging materials. The quality control department's release of packaging materials for use in packaging or labelling was inadequate.

10Laboratory and QC controls

The examination and/or approval of fabrication, packaging, labelling, testing, storage, and/or the transportation method and procedures by the person in charge of the quality control department before implementation was inadequate. The master production documents were inadequate.

11Laboratory and QC controls

The examination and/or approval of fabrication, packaging, labelling, testing, storage, and/or the transportation method and procedures by the person in charge of the quality control department before implementation was inadequate. The system for reviewing, revising, and approving standard operating procedures was inadequate. The procedure was inadequate for documenting quality control decisions by the person in charge of the quality control department.

12Contamination control

The drug was fabricated, packaged, labelled, and/or stored in premises that were not designed, constructed, and/or maintained to allow for effective cleaning, sanitary conditions, and/or the prevention of drug contamination.

13Other quality system

The availability, implementation, and/or quality of the written sanitation program was inadequate.

14Validation and qualification

Critical production processes were not validated. Validation studies were not conducted in keeping with the predefined protocols.

15Material and supplier control

The drug fabricator's specifications for raw materials were inadequate. The raw materials used to fabricate a drug were not tested against the specifications, did not comply with the specifications, and/or were expired.

16Equipment and facility

The controls were inadequate for creating, modifying, reviewing, storing, and/or retrieving records. The maintenance of evidence was inadequate for manufacturing, packaging, labelling, required testing, storage, and/or distribution, including the respective conditions. The establishment and/or the maintenance of a data governance plan was inadequate.

About this record

Extracted automatically from the document of the Health Canada inspection on 2023-02-08. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Novel Biome Solutions Inc. company profile — full history Health Canada documents, 2023 Go to Findings search